article thumbnail

STAT+: Generative AI is transforming radiology, and it’s only the beginning

STAT

By 2030, agreed a roomful of radiologists in Chicago this week, generative AI will be ubiquitous in their written work.  Products using LLMs to streamline radiology documentation dominated the demonstration hall, and several sessions centered on health technology’s latest poster child. 

article thumbnail

Tories pledge £250m each year for Pharmacy First 2027-2030

The Pharmacist

The Conservative Party has set out spending plans of £250m each year on Pharmacy First from 2027 to 2030, as it pledges to expand the service to include more conditions like acne and chest infections.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

billion by 2030. Since most pharmaceutical manufacturers export their products to North America and Europe, the need for documents such as process management, corrective and preventive actions (CAPA), deviations, training, quality management, and product release documents is vital.

article thumbnail

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT

 The company’s final study plan was submitted to the FDA in 2022 and is expected to be completed  by 2030 , according to FDA briefing documents published earlier this week. They were approved under the FDA accelerated pathway in 2009 and 2014, respectively, for treating a rare form of blood cancer. The

article thumbnail

GenAI adoption in India’s pharma sector signals operational shifts

Express Pharma

With 66 per cent of healthcare firms already piloting GenAI, we are seeing significant traction in areas like medical documentation, diagnostics, and revenue cycle management. As adoption scales, GenAI will play a crucial role in expanding healthcare access, especially in underserved regions, and optimising operational efficiencies.”

article thumbnail

The Hidden Risks in RPM Billing: What Every US Healthcare Practice Should Know in 2025

PharmD Live

By 2025, over 71 million Americans (26% of the population) are expected to use RPM services, with the US market projected to double to $29+ billion by 2030. Proven Track Record: Documented success, strong references, and positive client outcomes. billion by 2030 with 12.8% OEI-02-23-00260). link] MarketsandMarkets.

article thumbnail

Pharma’s strategic path to growth in the nutra maze

Express Pharma

billion by 2030, according to a GlobeNewsWire report. “It is not justifiable to compare pharma products, where a lot of work has already been done and well-documented with international harmonisation (e.g., The nutraceutical market is expanding rapidly, valued at $6.11 billion in 2024 and projected to reach $11.55